Accepted for/Published in: JMIR Serious Games
Date Submitted: Sep 15, 2023
Date Accepted: Jul 2, 2024
Apple Vision Pro for Healthcare: “The Ultimate Display”? Entering the Wonderland of Precision Medicine: A first Perspective and Survey
ABSTRACT
At the Worldwide Developers Conference (WWDC) in June 2023, Apple introduced the Vision Pro. The Vision Pro is a Mixed Reality (MR) headset, more specifically it is a Virtual Reality (VR) device with an additional Video See-Through (VST) capability. The VST capability turns the Vision Pro also into an Augmented Reality (AR) device. The AR feature is enabled by streaming the real world via cameras to the (VR) screens in front of the user’s eyes. This is of course not unique and similar to other devices, like the Varjo XR-3. Nevertheless, the Vision Pro has some interesting features, like an inside-out screen that can show the headset wearers’ eyes to “outsiders” or a button on the top, called “Digital Crown”, that allows you to seamlessly blend digital content with your physical space by turning it. In addition, it is untethered, except for the cable to the battery, which makes the headset more agile, compared to the Varjo XR-3. This could actually come closer to the “Ultimate Display”, which Ivan Sutherland had already sketched in 1965. After a great response from the media and social networks to the release, we were able to test and review the new Apple Vision Pro ourselves in March 2024. Including an expert survey with 13 of our colleagues after testing the Apple Vision Pro in our institute, this perspective want to see if the Apple Vision Pro can overcome some clinical challenges that - especially - AR still faces in the medical domain, but also go beyond and discuss if the Vision Pro could support clinicians in essential tasks to spend more time with their patients.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.